Navigation Links
11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill
Date:11/24/2008

CINCINNATI, Nov. 24 /PRNewswire/ -- Dr. Stephen Joffe, Craig Joffe, and Alan Buckey today filed an amendment to their Schedule 13D with the U.S. Securities and Exchange Commission. The group previously filed a 13D disclosing ownership of 11.4% of LCA-Vision, Inc. (Nasdaq: LCAV), which operates 77 LasikPlus fixed-site laser vision correction centers in 33 states in the United States. Dr. Joffe is the founder and former Chairman and CEO of LCAV. Craig Joffe is the former Chief Operating Officer and General Counsel of LCAV, and Alan Buckey is the former Executive Vice President of Finance and Chief Financial Officer of the Company. The three of them worked together as the executive management team of LCAV (Nasdaq: LCAV) to grow the market capitalization of the Company well in excess of 1000% from 2003-2006.

Having specifically expressed to LCAV's Board of Directors their willingness and unique ability to help the Board of Directors fix what they believe is effectively a broken company, the group was both saddened and in a state of disbelief to find earlier this morning that the Company had put in place a "stockholder rights plan," commonly known as a poison pill. This poison pill was put in place immediately following a letter dated November 21, 2008, the group sent to E. Anthony Woods, Chairman of the Board of Directors of LCA-Vision, and copied to the other Directors, stating that their actions were prompted by the systematic and dramatic destruction of value to the Company's shareholders, physicians and employees that the three of them worked together to create. LCAV's share price has fallen over 90% in the two years since Steve Straus was appointed CEO by LCA-Vision's Board of Directors.

In a letter to the Chairman of t
'/>"/>

SOURCE Steve Joffe
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Dynamics Research Corporation Awarded $11.4 Million Medical Healthcare Program Management Contract
2. Senator Norm Coleman Praised for Leading Successful Effort to Derail $11.4 Million Minnesota Medicare Cuts
3. Barr Shareholders Approve Pending Teva Acquisition
4. Cord Blood America Posts Letter to Shareholders: New Administrations Potential Enhanced Stem Cell Research Initiative Should Benefit the Company and Its Shareholders
5. Lees Pharmaceutical Kept Up the Rapid Pace of Growth; Profit Attributable to Shareholders Surged 176% in the Nine Months of 2008
6. MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares
7. Westaim terminates reorganization agreement and cancels shareholders meeting
8. GeneThera - CHANGING DIRECTIONS - an Update to Shareholders
9. Luoxin Announces 2008 Third Quarterly Results; Profit Attributable to Shareholders Surged 62.9% to Approximately RMB 138,141,000
10. Z Trim Holdings, Inc. Releases Letter to Shareholders
11. MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... According to a June 11, 2013 ABC News article, ... information surfaces about the negative effects of sun on ... one’s skin care routine, as the sun's rays ... , “I agree with the article's suggestions for the best ... of Epione Beverly Hills. “Apply a minimum of SPF 30, ...
(Date:6/17/2013)... Harvard Stem Cell Institute (HSCI) researchers have identified in ... to regulate embryonic stem cell self-renewal, beginning a creative ... , The gene, SALL4, gives stem cells their ability ... mature cells. Typically, cells only express SALL4 during embryonic ... cases of acute myeloid leukemia and 10 to 30 ...
(Date:6/17/2013)... childhood obesity, researchers at the Johns Hopkins Bloomberg ... are important. A systematic review of childhood obesity ... incorporate schools and focus on both diet and ... in children. The results of the study appear ... "In measuring the effectiveness of community-based programs that ...
(Date:6/17/2013)... pyrvinium pamoate inhibits aggressive forms of prostate cancer that ... conducted in an animal model. The results will be ... in San Francisco. , "Our novel prostate cancer drug ... lead author Jeremy Jones, PhD, assistant professor of molecular ... Duarte, CA. "Thus, it has the potential to treat ...
(Date:6/17/2013)... Reliable services of Link to Pay have been offered to ... can fix payment processing. , Schools and colleges have a ... fees from students and processing them may be a herculean ... cases, colleges and universities are looking for some smart solutions ... efficiently without any complications. , At the same time, parents ...
Breaking Medicine News(10 mins):Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:A new target for cancer drug development 2Health News:Community-based programs may help prevent childhood obesity 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2Health News:PayCanada Offers Link to Pay Services to its Customers 2
... Legislature,took an important step to help combat the rise ... according to the Michigan Dermatological Society,(MDS). , ... Frank Accavitti (D-Eastpointe), regulates,tanning salons by specifically requiring onsite ... tanning facilities listing potential health,consequences, and a signed informed ...
... company, explains the repercussions and risks of waiting to file for SSDI. ... ... the mistake of waiting too long to apply for Social Security disability ... people in the Social Security Disability Insurance (SSDI) process each ...
... With everyone mindful of,budgets and spending this holiday ... routine perfume or socks and to give gifts that ... too. Finding special gifts for loved ones with,asthma ... and allergy friendly(TM),Certification Program is helping holiday shoppers all ...
... Dec. 11 The following is a statement from Peter ... United States: , , The ... decline in underage drinking. The study,s authors point out that ... of alcohol by those under the legal drinking age. The ...
... Million Patient Pavilion , , CAMDEN, ... filled lobby as visitors gather in the coffee shop sipping lattes ... is the new patient Pavilion at Cooper University Hospital. Cooper celebrated ... a spectacular "Grand Lighting" of the Pavilion. , ...
... 11 Bioenergy Life Science -- The Ribose,Company ... Solutions, LLC, to market,Bioenergy D-Ribose(TM) in the Eastern ... to stimulate the synthesis of adenosine,triphosphate (ATP) -- ... "Collaborating with Xsto Solutions will ...
Cached Medicine News:Health News:Dermatologists Applaud Passage of Tanning Salon Regulation 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 3Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 4Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 2Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 3Health News:Cooper Opens Doors to New Era in Healthcare 2Health News:Cooper Opens Doors to New Era in Healthcare 3Health News:Bioenergy Life Science Retains Xsto Solutions to Market D-Ribose 2
(Date:6/17/2013)... TORONTO , June 17, 2013  Generex ... it entered into a securities purchase agreement with certain ... agreed to purchase in a private placement an aggregate ... Series E 9% Convertible Preferred Stock ("convertible preferred stock") ... 100% of the shares of its common stock issuable ...
(Date:6/17/2013)... -- Franciscan St. Francis Health Cancer Center today ... Indiana to use a new drug to treat ... Xofigo ®, a radiopharmaceutical used in patients with late-stage, ... was approved for use by the U.S. Food and Drug ... it may become castration-resistant, which has become resistant to medical ...
(Date:6/17/2013)... OSAKA, Japan , June 17, 2013 ... Takeda Pharmaceuticals U.S.A. , Inc. today ... KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and ... the United States (U.S.). These ... Administration (FDA) for the treatment of type 2 diabetes ...
Breaking Medicine Technology:Generex Announces $1,225,000 Capital Investment 2Generex Announces $1,225,000 Capital Investment 3Generex Announces $1,225,000 Capital Investment 4Generex Announces $1,225,000 Capital Investment 5New drug proving effective in attacking advanced prostate cancer 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 4Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 5Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 6Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 7Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 8Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 9
The Solar Radius Chair is a multi-functional and cost effective working environment. It can be used for simple and advanced urodynamic studies as well as for routine gynecology investigations....
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... Model BR2 Bilirubin STAT-Analyzer® provides a rapid, ... in neonates. And because it's so compact ... for virtually any laboratory. The Model BR2 ... the only instrument that measures total and ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: